<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03195517</url>
  </required_header>
  <id_info>
    <org_study_id>OPCuriamo-1</org_study_id>
    <nct_id>NCT03195517</nct_id>
  </id_info>
  <brief_title>Effects of Physical Training on Bone Turnover and Quality of Life in Osteopenic Postmenopausal Women.</brief_title>
  <official_title>Effects of a 3-month Weight-bearing and Resistance Exercise Training on Circulating Osteoprogenitor Cells and Bone Formation Markers in Postmenopausal Women With Low Bone Mass.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <brief_summary>
    <textblock>
      The aim of our research was to define both in vivo and in vitro whether and to what extent an
      high-impact exercise program would affect bone cell turnover and improve the QoL in
      osteopenic postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were selected among those attending the &quot;Bone and Mineral Metabolism Disorders&quot;
      Clinic of Perugia University, Italy, since May 2nd 2015 and January 31st 2016. A total of 33
      post-menopausal women volunteered to participate in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This was an interventional, single group assignment study in which the subjects were first assigned to the control group and, after 1-month interval with no physical training, were shifted into the 3-months exercise intervention group. Thus, the subjects acted as their own control at the end of the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation in Serum Levels of Procollagen 1 N-terminal Peptide (P1NP)</measure>
    <time_frame>Baseline - Week 4</time_frame>
    <description>P1NP is the most reliable serum marker of bone formation commercially available at the moment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation in Serum Levels of Procollagen 1 N-terminal Peptide (P1NP).</measure>
    <time_frame>Week 4 - Week 12</time_frame>
    <description>P1NP is the most reliable serum marker of bone formation, commercially available at the moment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Sclerotin Levels</measure>
    <time_frame>Baseline - W4</time_frame>
    <description>Sclerostin has been proposed as the check-point where physical activity (PA) acts to modulate bone metabolism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sclerostin</measure>
    <time_frame>Week 4 - Week 12</time_frame>
    <description>Sclerostin has been proposed as the check-point where PA acts to modulate bone metabolism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation in Serum Carboxy-terminal Telopeptide of Collagen Type I (sCTX)</measure>
    <time_frame>Baseline - Week 4</time_frame>
    <description>Serum carboxy-terminal telopeptide of collagen type I (sCTX) is one of the most sensitive and specific bone resorption markers of osteoclast-mediated collagen degradation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of Serum Carboxy Terminal Telopeptide of Collagen Type I (sCTX)</measure>
    <time_frame>Week 4 - Week 12</time_frame>
    <description>Serum carboxy terminal telopeptide of collagen type I (sCTX) is one of the most sensitive and specific bone resorption markers of osteoclast-mediated collagen degradation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation in Circulating Osteoprogenitor Cells (OPCs)</measure>
    <time_frame>Baseline - Week 4</time_frame>
    <description>Measurements of circulating OPCs with stem cell characteristics (CD34+) and express bone-specific proteins such as alkaline phosphatase (AP +) and osteocalcin (OCN +).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation in Circulating Osteoprogenitor Cells (OPCs).</measure>
    <time_frame>Week 4 - Week 12</time_frame>
    <description>Measurements of circulating OPCs with stem cell characteristics (CD34+) and express bone-specific proteins such as alkaline phosphatase (AP +) and osteocalcin (OCN +).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation in Health-related Quality of Life (QoL)</measure>
    <time_frame>Baseline - Week 4</time_frame>
    <description>Health-related Quality of Life evaluated using the Quality of Life questionnaire of the European Foundation for Osteoporosis (QUALEFFO). The score ranges from 0, corresponding to the best QoL, to 100, corresponding to the worst QoL. Total score is the average value of 5 sub scores, corresponding to pain, physical function, mental function, social function and general health perception.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in Health-related Quality of Life (QoL).</measure>
    <time_frame>Week 4 - Week 12</time_frame>
    <description>Health-related Quality of Life evaluated using the Quality of Life questionnaire of the European Foundation for Osteoporosis (QUALEFFO). The score ranges from 0, corresponding to the best QoL, to 100, corresponding to the worst QoL. Total score is the average value of 5 sub scores, corresponding to pain, physical function, mental function, social function and general health perception.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Osteopenia</condition>
  <condition>Bone Turnover Markers</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Physical Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The exercise program was performed at C.U.R.I.A.Mo. Institute of &quot;Universit√† degli Studi di Perugia&quot;. Twenty-four exercise sessions were provided, carried out twice a week for three months. Each session was supervised by two graduated trainers and two medical doctors with a maximum attendance of 5 patient/group.
Each session lasted 45 minutes divided into 15 minutes of aerobic activity and 30 minutes of weight-bearing and resistance activities.
This latter section was specifically projected for adults and older adults with increased risk of fractures and was intended to improve muscle strength and flexibility, balance and, as a result, to prevent the risk of falls.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No additional physical exercise</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual recommendations for prevention of fractures in adults and elderly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical exercise</intervention_name>
    <arm_group_label>Physical Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  postmenopausal

          -  bone mineral density T-score less than -1 but more than -2.5 in the total hip or
             lumbar spine (L1-L4) by dual energy x-ray absorptiometry

          -  be able to attend an exercise program 2 times per week over the 3-month period

          -  stated availability throughout the entire study period

        Exclusion Criteria:

          -  secondary causes of bone loss such as osteomalacia, glucocorticoid medication

          -  co-morbidities that would interfere with participation in exercise such as severe
             heart or pulmonary disease, inflammatory joint disease, severe osteoarthritis,
             psychiatric condition

          -  physical or orthopaedic disabilities that would place the subject at risk or limit
             their ability to perform exercise

          -  a past vertebral fracture

          -  history of chronic diseases, such as renal, hepatic, cardiac, and rheumatic diseases

          -  current or prior use of drugs that could interfere with bone mass (i.e.
             glucocorticoids, antiresorptive drugs and hormonal replacement therapy)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>52 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lombardini</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Perugia, Italy</affiliation>
  </overall_official>
  <reference>
    <citation>Turner CH, Robling AG. Mechanisms by which exercise improves bone strength. J Bone Miner Metab. 2005;23 Suppl:16-22. Review.</citation>
    <PMID>15984409</PMID>
  </reference>
  <reference>
    <citation>Pasqualini L, Leli C, Ministrini S, Schillaci G, Zappavigna RM, Lombardini R, Scarponi AM, Mannarino E. Relationships between global physical activity and bone mineral density in a group of male and female students. J Sports Med Phys Fitness. 2017 Mar;57(3):238-243. doi: 10.23736/S0022-4707.16.06054-0. Epub 2016 May 31.</citation>
    <PMID>27244129</PMID>
  </reference>
  <reference>
    <citation>Martyn-St James M, Carroll S. A meta-analysis of impact exercise on postmenopausal bone loss: the case for mixed loading exercise programmes. Br J Sports Med. 2009 Dec;43(12):898-908. doi: 10.1136/bjsm.2008.052704. Epub 2008 Nov 3. Review.</citation>
    <PMID>18981037</PMID>
  </reference>
  <reference>
    <citation>Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008 Feb 29;283(9):5866-75. Epub 2007 Dec 17.</citation>
    <PMID>18089564</PMID>
  </reference>
  <reference>
    <citation>Li WC, Chen YC, Yang RS, Tsauo JY. Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta-analysis. Clin Rehabil. 2009 Oct;23(10):888-96. doi: 10.1177/0269215509339002. Epub 2009 Aug 28. Review.</citation>
    <PMID>19717503</PMID>
  </reference>
  <reference>
    <citation>Pirro M, Leli C, Fabbriciani G, Manfredelli MR, Callarelli L, Bagaglia F, Scarponi AM, Mannarino E. Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis. Osteoporos Int. 2010 Feb;21(2):297-306. doi: 10.1007/s00198-009-0968-0. Epub 2009 May 30.</citation>
    <PMID>19484167</PMID>
  </reference>
  <reference>
    <citation>Lips P, Leplege A (2000). Development and validation of quality of life questionnaire for patients with vertebral fractures: Qualeffo-41. Quality of Life Research 9(6a):763-766.</citation>
  </reference>
  <reference>
    <citation>Adami S, Gatti D, Viapiana O, Fiore CE, Nuti R, Luisetto G, Ponte M, Rossini M; BONTURNO Study Group. Physical activity and bone turnover markers: a cross-sectional and a longitudinal study. Calcif Tissue Int. 2008 Dec;83(6):388-92. doi: 10.1007/s00223-008-9184-8. Epub 2008 Oct 24.</citation>
    <PMID>18949504</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 15, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <results_first_submitted>October 31, 2017</results_first_submitted>
  <results_first_submitted_qc>September 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2019</results_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Rita Lombardini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Osteopenia</keyword>
  <keyword>Physical activity</keyword>
  <keyword>Bone turnover markers</keyword>
  <keyword>Osteoprogenitor cells</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control/Exercise Training</title>
          <description>At the start of the study, all participants were assigned to 1-month non-exercise control group. Measurements of bone formation markers, circulating osteoprogenitor cells and health-related quality of life were evaluated at the time of enrollment and after 1 month run-in.
All study participants, assigned to 1-month non-exercise control group, were shifted into the exercise intervention group. Measurements of bone formation markers, circulating osteoprogenitor cells, physical fitness and health-related quality of life were evaluated after 3-months of high-impact exercise training.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control/Exercise Training</title>
          <description>33 osteopenic postmenopausal women were included in the study. Bone formation markers, circulating osteoprogenitor cells and health-related quality of life were evaluated at the time of enrollment, after 1 month run-in and after 3 months of high-impact exercise training.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Variation in Serum Levels of Procollagen 1 N-terminal Peptide (P1NP)</title>
        <description>P1NP is the most reliable serum marker of bone formation commercially available at the moment</description>
        <time_frame>Baseline - Week 4</time_frame>
        <population>Post-menopausal women with low bone mass at dual energy X-ray absorptiometry (DEXA) measurement, compatible with osteopenia (T-score between -1 DS and -2.5 DS)</population>
        <group_list>
          <group group_id="O1">
            <title>No Additional Physical Exercise</title>
            <description>Usual recommendations for prevention of fractures in adults and elderly.</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Serum Levels of Procollagen 1 N-terminal Peptide (P1NP)</title>
          <description>P1NP is the most reliable serum marker of bone formation commercially available at the moment</description>
          <population>Post-menopausal women with low bone mass at dual energy X-ray absorptiometry (DEXA) measurement, compatible with osteopenia (T-score between -1 DS and -2.5 DS)</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P1NP, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.34" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P1NP, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.91" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Variation in Serum Levels of Procollagen 1 N-terminal Peptide (P1NP).</title>
        <description>P1NP is the most reliable serum marker of bone formation, commercially available at the moment.</description>
        <time_frame>Week 4 - Week 12</time_frame>
        <population>Post-menopausal women with low bone mass at DEXA measurement, compatible with osteopenia (T-score between -1 DS and -2.5 DS)</population>
        <group_list>
          <group group_id="O1">
            <title>Physical Exercise</title>
            <description>The exercise program was performed at C.U.R.I.A.Mo. Institute of &quot;Universit√† degli Studi di Perugia&quot;. Twenty-four exercise sessions were provided, carried out twice a week for three months. Each session was supervised by two graduated trainers and two medical doctors with a maximum attendance of 5 patient/group.
Each session lasted 45 minutes divided into 15 minutes of aerobic activity and 30 minutes of weight-bearing and resistance activities.
This latter section was specifically projected for adults and older adults with increased risk of fractures and was intended to improve muscle strength and flexibility, balance and, as a result, to prevent the risk of falls.
Physical exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Serum Levels of Procollagen 1 N-terminal Peptide (P1NP).</title>
          <description>P1NP is the most reliable serum marker of bone formation, commercially available at the moment.</description>
          <population>Post-menopausal women with low bone mass at DEXA measurement, compatible with osteopenia (T-score between -1 DS and -2.5 DS)</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P1NP, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.91" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P1NP, W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.87" spread="12.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Sclerotin Levels</title>
        <description>Sclerostin has been proposed as the check-point where physical activity (PA) acts to modulate bone metabolism.</description>
        <time_frame>Baseline - W4</time_frame>
        <population>Post-menopausal women with low bone mass at DEXA measurement, compatible with osteopenia (T-score between -1 DS and -2.5 DS)</population>
        <group_list>
          <group group_id="O1">
            <title>No Additional Physical Exercise</title>
            <description>Usual recommendations for prevention of fractures in adults and elderly.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Sclerotin Levels</title>
          <description>Sclerostin has been proposed as the check-point where physical activity (PA) acts to modulate bone metabolism.</description>
          <population>Post-menopausal women with low bone mass at DEXA measurement, compatible with osteopenia (T-score between -1 DS and -2.5 DS)</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sclerostin, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.76" spread="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sclerostin, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.30" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sclerostin</title>
        <description>Sclerostin has been proposed as the check-point where PA acts to modulate bone metabolism.</description>
        <time_frame>Week 4 - Week 12</time_frame>
        <population>Post-menopausal women with low bone mass at DEXA measurement, compatible with osteopenia (T-score between -1 DS and -2.5 DS).</population>
        <group_list>
          <group group_id="O1">
            <title>Physical Exercise</title>
            <description>The exercise program was performed at C.U.R.I.A.Mo. Institute of &quot;Universit√† degli Studi di Perugia&quot;. Twenty-four exercise sessions were provided, carried out twice a week for three months. Each session was supervised by two graduated trainers and two medical doctors with a maximum attendance of 5 patient/group.
Each session lasted 45 minutes divided into 15 minutes of aerobic activity and 30 minutes of weight-bearing and resistance activities.
This latter section was specifically projected for adults and older adults with increased risk of fractures and was intended to improve muscle strength and flexibility, balance and, as a result, to prevent the risk of falls.
Physical exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Sclerostin</title>
          <description>Sclerostin has been proposed as the check-point where PA acts to modulate bone metabolism.</description>
          <population>Post-menopausal women with low bone mass at DEXA measurement, compatible with osteopenia (T-score between -1 DS and -2.5 DS).</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sclerostin, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.30" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sclerostin, W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.96" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Variation in Serum Carboxy-terminal Telopeptide of Collagen Type I (sCTX)</title>
        <description>Serum carboxy-terminal telopeptide of collagen type I (sCTX) is one of the most sensitive and specific bone resorption markers of osteoclast-mediated collagen degradation</description>
        <time_frame>Baseline - Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control/Exercise Training</title>
            <description>Usual care and no additional physical exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Serum Carboxy-terminal Telopeptide of Collagen Type I (sCTX)</title>
          <description>Serum carboxy-terminal telopeptide of collagen type I (sCTX) is one of the most sensitive and specific bone resorption markers of osteoclast-mediated collagen degradation</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sCTX baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCTX, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Variation of Serum Carboxy Terminal Telopeptide of Collagen Type I (sCTX)</title>
        <description>Serum carboxy terminal telopeptide of collagen type I (sCTX) is one of the most sensitive and specific bone resorption markers of osteoclast-mediated collagen degradation.</description>
        <time_frame>Week 4 - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control/Exercise Training</title>
            <description>The exercise program was performed at C.U.R.I.A.Mo. Healthy Lifestyle Institute of Perugia University.
The program provided 24 exercise sessions supervised by 2 physical education instructors and 2 medical researchers with a maximum attendance of 5 patient/group and carried out twice a week for three months.
Each session lasted approximately 45 minutes divided into 15 minutes of cardiovascular activity performed using various ergometers and 30 minutes of weight-bearing endurance activities, resistance training and other exercise to develop balance and prevent falls, organized according to circuit training methodology.
The great part of the exercise included in the program aim to provide variably strains (compression, bending, twisting) distributed across an higher surface of the femoral neck, to produce a maximal osteogenic response.</description>
          </group>
        </group_list>
        <measure>
          <title>Variation of Serum Carboxy Terminal Telopeptide of Collagen Type I (sCTX)</title>
          <description>Serum carboxy terminal telopeptide of collagen type I (sCTX) is one of the most sensitive and specific bone resorption markers of osteoclast-mediated collagen degradation.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sCTX, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCTX, W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Variation in Circulating Osteoprogenitor Cells (OPCs)</title>
        <description>Measurements of circulating OPCs with stem cell characteristics (CD34+) and express bone-specific proteins such as alkaline phosphatase (AP +) and osteocalcin (OCN +).</description>
        <time_frame>Baseline - Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control/Exercise Training</title>
            <description>Usual care and no additional physical exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Circulating Osteoprogenitor Cells (OPCs)</title>
          <description>Measurements of circulating OPCs with stem cell characteristics (CD34+) and express bone-specific proteins such as alkaline phosphatase (AP +) and osteocalcin (OCN +).</description>
          <units>cells/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OCN+/CD34+ baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1304.94" spread="782.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OCN+/CD34+, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1393.92" spread="687.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OCN+/AP+ baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4485.21" spread="1690.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OCN+/AP+, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4512.60" spread="1658.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Variation in Circulating Osteoprogenitor Cells (OPCs).</title>
        <description>Measurements of circulating OPCs with stem cell characteristics (CD34+) and express bone-specific proteins such as alkaline phosphatase (AP +) and osteocalcin (OCN +).</description>
        <time_frame>Week 4 - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control/Exercise Training</title>
            <description>The exercise program was performed at C.U.R.I.A.Mo. Healthy Lifestyle Institute of Perugia University.
The program provided 24 exercise sessions supervised by 2 physical education instructors and 2 medical researchers with a maximum attendance of 5 patient/group and carried out twice a week for three months.
Each session lasted approximately 45 minutes divided into 15 minutes of cardiovascular activity performed using various ergometers and 30 minutes of weight-bearing endurance activities, resistance training and other exercise to develop balance and prevent falls, organized according to circuit training methodology.
The great part of the exercise included in the program aim to provide variably strains (compression, bending, twisting) distributed across an higher surface of the femoral neck, to produce a maximal osteogenic response.</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Circulating Osteoprogenitor Cells (OPCs).</title>
          <description>Measurements of circulating OPCs with stem cell characteristics (CD34+) and express bone-specific proteins such as alkaline phosphatase (AP +) and osteocalcin (OCN +).</description>
          <units>cells/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OCN+/CD34+, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1393.92" spread="687.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OCN+/CD34+, W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2311.82" spread="1356.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OCN+/AP+, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4512.60" spread="1658.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OCN+/AP+, W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5062.00" spread="1975.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variation in Health-related Quality of Life (QoL)</title>
        <description>Health-related Quality of Life evaluated using the Quality of Life questionnaire of the European Foundation for Osteoporosis (QUALEFFO). The score ranges from 0, corresponding to the best QoL, to 100, corresponding to the worst QoL. Total score is the average value of 5 sub scores, corresponding to pain, physical function, mental function, social function and general health perception.</description>
        <time_frame>Baseline - Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control/Exercise Training</title>
            <description>At the start of the study, all participants were assigned to 1-month non-exercise control group. Measurements of bone formation markers, circulating osteoprogenitor cells and health-related quality of life were evaluated at the time of enrollment and after 1 month run-in.
All study participants, assigned to 1-month non-exercise control group, were shifted into the exercise intervention group. Measurements of bone formation markers, circulating osteoprogenitor cells, physical fitness and health-related quality of life were evaluated after 3-months of high-impact exercise training.</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Health-related Quality of Life (QoL)</title>
          <description>Health-related Quality of Life evaluated using the Quality of Life questionnaire of the European Foundation for Osteoporosis (QUALEFFO). The score ranges from 0, corresponding to the best QoL, to 100, corresponding to the worst QoL. Total score is the average value of 5 sub scores, corresponding to pain, physical function, mental function, social function and general health perception.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.59" spread="17.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.97" spread="19.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical function, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.89" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physica function, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.75" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social function, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.38" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social function, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.77" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perception, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.23" spread="14.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perception, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.29" spread="14.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental function, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.20" spread="10.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental function, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.09" spread="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total score, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.51" spread="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total score, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.70" spread="7.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variation in Health-related Quality of Life (QoL).</title>
        <description>Health-related Quality of Life evaluated using the Quality of Life questionnaire of the European Foundation for Osteoporosis (QUALEFFO). The score ranges from 0, corresponding to the best QoL, to 100, corresponding to the worst QoL. Total score is the average value of 5 sub scores, corresponding to pain, physical function, mental function, social function and general health perception.</description>
        <time_frame>Week 4 - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control/Exercise Training</title>
            <description>At the start of the study, all participants were assigned to 1-month non-exercise control group. Measurements of bone formation markers, circulating osteoprogenitor cells and health-related quality of life were evaluated at the time of enrollment and after 1 month run-in.
All study participants, assigned to 1-month non-exercise control group, were shifted into the exercise intervention group. Measurements of bone formation markers, circulating osteoprogenitor cells, physical fitness and health-related quality of life were evaluated after 3-months of high-impact exercise training.</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Health-related Quality of Life (QoL).</title>
          <description>Health-related Quality of Life evaluated using the Quality of Life questionnaire of the European Foundation for Osteoporosis (QUALEFFO). The score ranges from 0, corresponding to the best QoL, to 100, corresponding to the worst QoL. Total score is the average value of 5 sub scores, corresponding to pain, physical function, mental function, social function and general health perception.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.97" spread="19.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical function, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.75" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social function, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.77" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perception, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.29" spread="14.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental function, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.09" spread="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total score, W4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.70" spread="7.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.36" spread="12.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical function, W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.13" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social function, W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.10" spread="12.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perception, W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.66" spread="14.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental function, W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.55" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total score, W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.55" spread="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control/Exercise Training</title>
          <description>At the start of the study, all participants were assigned to 1-month non-exercise control group. Measurements of bone formation markers, circulating osteoprogenitor cells and health-related quality of life were evaluated at the time of enrollment and after 1 month run-in.
All study participants, assigned to 1-month non-exercise control group, were shifted into the exercise intervention group. Measurements of bone formation markers, circulating osteoprogenitor cells, physical fitness and health-related quality of life were evaluated after 3-months of high-impact exercise training.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Short duration of the observation (12 weeks). Small number of the sample. We did not provide any confirmation of the effects of the exercise program in terms of bone mineral density (BMD) or fracture risk.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Rita Lombardini</name_or_title>
      <organization>University of Perugia - Italy</organization>
      <phone>+39 075 578 4027</phone>
      <email>rita.lombardini@unipg.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

